Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AKCEA THERAPEUTICS, INC.AKCA · Entity 145982 | Director | July 13, 2017 | July 13, 2017 |
| IONIS PHARMACEUTICALS INCIONS · Entity 1182 | Director · Exec Chairman of the Board | January 26, 2021 | January 29, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AKCEA THERAPEUTICS, INC.
Report date July 13, 2017 · Filed July 13, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| No securities are beneficially owned.SEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2017-07-13 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
IONIS PHARMACEUTICALS INC
Report date January 26, 2021 · Filed January 29, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,021 |
Reported balance
After 2021-01-26 transaction · row 1
1 source rowRow 1 · 2021-01-26 · Sale · Disposed 28,333 · Balance 2,021 F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020. F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.00 to $64.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4. |
| Common StockSEC Table I · non-derivative | IndirectBy wife | 3,111 |
Reported balance
Holding disclosure · report date 2021-01-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,111 |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 494,391 |
Reported balance
Holding disclosure · report date 2021-01-26 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 494,391 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020.
F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.00 to $64.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 354 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000013 · edgar.xml · derivative · entry 25 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 354 Underlying: Common Stock · 354 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2014. F14 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F14 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 416 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000013 · edgar.xml · derivative · entry 24 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 0 Underlying: Common Stock · 416 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F10 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2013. F14 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F14 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 8,133 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000013 · edgar.xml · derivative · entry 23 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,397 Underlying: Common Stock · 8,133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F8 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2016. F14 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F14 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 6,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000013 · edgar.xml · derivative · entry 22 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 6,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F6 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2015. F14 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F14 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 7,812 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000013 · edgar.xml · derivative · entry 21 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,812 Underlying: Common Stock · 7,812 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 15, 2014. F14 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F14 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 5,547 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000013 · edgar.xml · derivative · entry 20 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,547 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice, dated January 30, 2013. F14 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F14 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Units · Derivative | 2,692 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000013 · edgar.xml · derivative · entry 19 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 2,692 Underlying: Common Stock · 2,692 shares Expires not disclosed F11 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F13 · derivative.exercise_date: Grant 1/15/2017 to reporting person's wife of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on January 15, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2021. The RSU is vested as to 0 shares on January 15, 2017. F13 · derivative.expiration_date: Grant 1/15/2017 to reporting person's wife of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on January 15, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2021. The RSU is vested as to 0 shares on January 15, 2017. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Units · Derivative | 27,168 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000013 · edgar.xml · derivative · entry 18 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,168 Underlying: Common Stock · 27,168 shares Expires not disclosed F11 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F12 · derivative.exercise_date: Grant 1/15/2017 to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on January 15, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2021. The RSU is vested as to 0 shares on January 15, 2017. F12 · derivative.expiration_date: Grant 1/15/2017 to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on January 15, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on January 15, 2021. The RSU is vested as to 0 shares on January 15, 2017. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 334 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000013 · edgar.xml · nonDerivative · entry 15 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 3,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2016. F7 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2016. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 363 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000013 · edgar.xml · nonDerivative · entry 13 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 3,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2015. F5 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2015. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 354 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000013 · edgar.xml · nonDerivative · entry 11 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 2,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2014. F3 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2014. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 416 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000013 · edgar.xml · nonDerivative · entry 9 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 2,586 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2013. F9 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2013. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 8,133 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000013 · edgar.xml · nonDerivative · entry 7 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2016. F7 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2016. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 6,875 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000013 · edgar.xml · nonDerivative · entry 5 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,019 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2015. F5 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2015. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 7,812 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000013 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2014. F3 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 15, 2014. Read SEC document |
| January 15, 2017 Filed Jan 18, 2017 23:36 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 5,547 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000013 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 30, 2013. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit award granted on January 30, 2013. Read SEC document |
| January 10, 2017 Filed Jan 12, 2017 23:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,200 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-17-000009 · edgar.xml · derivative · entry 7 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 2,600 Underlying: Common Stock · 1,200 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2017 Filed Jan 12, 2017 23:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-17-000009 · edgar.xml · derivative · entry 6 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,462 Underlying: Common Stock · 12,000 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2017 Filed Jan 12, 2017 23:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 1,200 | $49.25 | $59,100.00 |
DisclosureSEC source: 0000874015-17-000009 · edgar.xml · nonDerivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 2,170 F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.12 to $49.38, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| January 10, 2017 Filed Jan 12, 2017 23:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,200 | $10.29 | $12,348.00 |
DisclosureSEC source: 0000874015-17-000009 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 3,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. Read SEC document |
| January 10, 2017 Filed Jan 12, 2017 23:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 12,000 | $49.25 | $591,000.00 |
DisclosureSEC source: 0000874015-17-000009 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,029 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.12 to $49.38, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| January 10, 2017 Filed Jan 12, 2017 23:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 12,000 | $7.25 | $87,000.00 |
DisclosureSEC source: 0000874015-17-000009 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. Read SEC document |
| January 04, 2017 Filed Jan 4, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 700 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-17-000008 · edgar.xml · derivative · entry 19 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 3,800 Underlying: Common Stock · 700 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2017 Filed Jan 4, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-17-000008 · edgar.xml · derivative · entry 18 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,462 Underlying: Common Stock · 7,000 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2017 Filed Jan 4, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 700 | $50.10 | $35,070.00 |
DisclosureSEC source: 0000874015-17-000008 · edgar.xml · nonDerivative · entry 12 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 2,170 F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. Read SEC document |
| January 04, 2017 Filed Jan 4, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 700 | $10.29 | $7,203.00 |
DisclosureSEC source: 0000874015-17-000008 · edgar.xml · nonDerivative · entry 11 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 2,870 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. Read SEC document |
| January 04, 2017 Filed Jan 4, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 7,000 | $50.10 | $350,700.00 |
DisclosureSEC source: 0000874015-17-000008 · edgar.xml · nonDerivative · entry 10 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,029 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. Read SEC document |
| January 04, 2017 Filed Jan 4, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 7,000 | $7.25 | $50,750.00 |
DisclosureSEC source: 0000874015-17-000008 · edgar.xml · nonDerivative · entry 9 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-17-000008 · edgar.xml · derivative · entry 17 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 4,500 Underlying: Common Stock · 1,000 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-17-000008 · edgar.xml · derivative · entry 16 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,462 Underlying: Common Stock · 10,000 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantEmployee Stock Option (right to buy) · Derivative | 16,157 | $0.00 Strike: $47.34 | $0.00 |
DisclosureSEC source: 0000874015-17-000008 · edgar.xml · derivative · entry 15 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 16,157 Underlying: Common Stock · 16,157 shares Expires 2024-01-02 F4 · derivative.exercise_date: Grant of 1/3/2017 to reporting person's wife of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/3/2018. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 4,039 shares per year. Following this transaction, the option was exercisable as to 0 on 1/3/2017. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantEmployee Stock Option (right to buy) · Derivative | 163,013 | $0.00 Strike: $47.34 | $0.00 |
DisclosureSEC source: 0000874015-17-000008 · edgar.xml · derivative · entry 14 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,013 Underlying: Common Stock · 163,013 shares Expires 2024-01-02 F3 · derivative.exercise_date: Grant of 1/3/2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/3/2018. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 40,753 shares per year. Following this transaction, the option was exercisable as to 0 on 1/3/2017. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 500 | $48.80 | $24,400.00 |
DisclosureSEC source: 0000874015-17-000008 · edgar.xml · nonDerivative · entry 8 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 2,170 F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 500 | $10.29 | $5,145.00 |
DisclosureSEC source: 0000874015-17-000008 · edgar.xml · nonDerivative · entry 7 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 2,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 500 | $47.30 | $23,650.00 |
DisclosureSEC source: 0000874015-17-000008 · edgar.xml · nonDerivative · entry 6 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 2,170 F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 500 | $10.29 | $5,145.00 |
DisclosureSEC source: 0000874015-17-000008 · edgar.xml · nonDerivative · entry 5 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 2,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. F2 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 5,000 | $48.80 | $244,000.00 |
DisclosureSEC source: 0000874015-17-000008 · edgar.xml · nonDerivative · entry 4 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,029 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 5,000 | $7.25 | $36,250.00 |
DisclosureSEC source: 0000874015-17-000008 · edgar.xml · nonDerivative · entry 3 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 5,000 | $47.30 | $236,500.00 |
DisclosureSEC source: 0000874015-17-000008 · edgar.xml · nonDerivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,029 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 23:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 5,000 | $7.25 | $36,250.00 |
DisclosureSEC source: 0000874015-17-000008 · edgar.xml · nonDerivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 23:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-16-000144 · edgar.xml · derivative · entry 20 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 5,500 Underlying: Common Stock · 1,000 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 23:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-16-000144 · edgar.xml · derivative · entry 19 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,462 Underlying: Common Stock · 10,000 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 23:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 1,000 | $42.22 | $42,220.00 |
DisclosureSEC source: 0000874015-16-000144 · edgar.xml · nonDerivative · entry 14 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 2,170 F4 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2016. F4 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2016. Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 23:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 1,000 | $10.29 | $10,290.00 |
DisclosureSEC source: 0000874015-16-000144 · edgar.xml · nonDerivative · entry 13 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 3,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2016. F4 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2016. Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 23:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 10,000 | $40.23 | $402,300.00 |
DisclosureSEC source: 0000874015-16-000144 · edgar.xml · nonDerivative · entry 12 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,029 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.22 to $40.33, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) on this Form 4. Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 23:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 10,000 | $7.25 | $72,500.00 |
DisclosureSEC source: 0000874015-16-000144 · edgar.xml · nonDerivative · entry 11 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 23:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-16-000144 · edgar.xml · derivative · entry 18 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 6,500 Underlying: Common Stock · 2,000 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 23:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,741 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-16-000144 · edgar.xml · derivative · entry 17 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,462 Underlying: Common Stock · 3,741 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 23:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 16,259 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0000874015-16-000144 · edgar.xml · derivative · entry 16 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,259 shares Expires 2018-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 23:51 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 1,000 | $37.25 | $37,250.00 |
DisclosureSEC source: 0000874015-16-000144 · edgar.xml · nonDerivative · entry 10 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 2,170 F4 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2016. F4 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2016. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.50, inclusive. The reporting person's wife undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) on this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.